Ces radiol. 2013, 67(2):142-147

PET/CT with the application of 18F-fluorocholine - the first experience with therapy response assessment after trans-arterial embolisation of the hepatocellular carcinomaOriginal article

Jiří Ferda1, Eva Ferdová1, Petr Duras1, Hynek Mírka1, Jan Baxa1, Ondřej Daum2, Tomáš Skalický3, Vladislav Třeška3
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Šiklův ústav patologické anatomie LF UK a FN, Plzeň
3 Chirurgická klinika LF UK a FN, Plzeň

Aim: To evaluate an early experience with 18F-FCH-PET/CT in the therapy response assessments after trans-arterial embolisations of hepatocellular carcinoma (HCC).

Method: The sample 18F-FCH-PET/CT examinations was assessed in five men (mean age 69.6 years range 59-83) suffered from HCC after trans-arterial embolisation. All examinations were performed after intravenous administration of 18F-gluorocholine in the dose of 2 MBq per kilogram of body weight, the full diagnostic dual-phase MDCT forms the integral part of the examination. The vascularisation and the radiopharmaceutical accumulation were assessed.

Results: The well differentiated HCC was present in all patients. Signs of the recurrence were found in four men, hyper-metabolic all of them, in three, joined with hyper-vascularisation. But the increased 18F-FCH uptake was depicted in area less than one third of hypervascularized tissue. Hypo-vascularized hyper-metabolic viable tissue of HCC was found in one patient. Newly developed HCC foci were found in two patients.

Conclusion: 18F-FCH-PET/CT is useful tool in the therapy response assessments in interventional therapy of HCC; information obtained about metabolism activity is more precise than evaluations based only on morphological information of CT.

Keywords: 18F-fluorocholine, PET/CT, hepatocelullar carcinoma, trans-arterial embolisations, drug-eluting beads
Grants and funding:

Práce byla podpořena Programem rozvoje vědních oborů Karlovy Univerzity (projekt P36).

Accepted: April 19, 2013; Published: June 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Ferdová E, Duras P, Mírka H, Baxa J, Daum O, et al.. PET/CT with the application of 18F-fluorocholine - the first experience with therapy response assessment after trans-arterial embolisation of the hepatocellular carcinoma. Ces radiol. 2013;67(2):142-147.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773. Go to original source... Go to PubMed...
    2. Varela M, Real MI, Burrel M, et al. Chemoembolisation of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481. Go to original source... Go to PubMed...
    3. Lencioni R, de Baere T, Murrel M, et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012; 35: 980-985. Go to original source... Go to PubMed...
    4. Lammer J, Malagari K, Vogl T, et al. Prospective randomised study of doxorubicin-eluting-bead embolisation in the treatment of hepatocellular carcinoma: results of the PRECISSION V study. Cardiovasc Intervent Radiol 2010; 33: 41-45. Go to original source... Go to PubMed...
    5. Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, Grahek D, Montravers F, Poupon R, Rosmorduc O. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F] FDG PET/CT. Eur J Nucl Med Mol Imaging 2006; 33(11): 1285-1289. Go to original source... Go to PubMed...
    6. Ferdová E, Ferda J, Daum O, Třeška V, Záhlava J. Komplementární úloha dvoufázové MDCT-angiografie a 18F-FDG-PET v hybridním zobrazení PET/CT hepatocelulárního karcinomu. Ces Radiol 2007; 61(1): 44-53.
    7. Zizka J, Klzo L, Ferda J, Mrklovský M, Bukac J. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol. Eur J Radiol 2007; 62(2): 186-191. Go to original source... Go to PubMed...
    8. Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, Huchet V, Ancel D, Grange JD, Rosmorduc O. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010; 51(11): 1699-1706. Go to original source... Go to PubMed...
    9. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging 2010; 37(11): 2188-2193. Go to original source... Go to PubMed...
    10. Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 2007; 37(6): 420-428. Go to original source... Go to PubMed...
    11. Fartoux L, Balogova S, Nataf V, Kerrou K, Huchet V, Rosmorduc O, Talbot JN. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nucl Med Commun 2012; 33(7): 757-765. Go to original source... Go to PubMed...
    12. van den Esschert JW, Bieze M, Beuers UH, van Gulik TM, Bennink RJ. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-fluorocholine PET/CT. Eur J Nucl Med Mol Imaging 2011; 38(3): 436-440. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content